Dr.ย Sangeetaย Goswami
MBBS, MD, PhD, Board Certified โ Internal Medicine & Medical Oncology
Associate Professor (Tenured), Genitourinary Medical Oncology
corporate_fareMD Anderson Cancer Center, Houston, TX
Sangeeta Goswami
MBBS, MD, PhD, Board Certified โ Internal Medicine & Medical Oncology
Dr. Sangeeta Goswami is a tenured Associate Professor in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, with a joint appointment in the Department of Immunology. She is also a Member of the James P. Allison Institute โ the immunotherapy research hub co-founded by Nobel Laureate Dr. James Allison. With over 23 years of clinical and research experience, she is a recognised expert in kidney cancer, bladder cancer, and prostate cancer, with specialised expertise in immunotherapy and epigenetic regulation of immune responses.
Dr. Goswami completed her MBBS at Gauhati Medical College in Assam, India, before moving to the United States for doctoral training in Immunology at Baylor College of Medicine (PhD, 2009). She subsequently completed her clinical residency at the University of Pittsburgh Medical Center and her Haematology-Oncology fellowship at MD Anderson Cancer Center (2016). Since joining MD Anderson faculty in 2016, she has risen to a tenured Associate Professorship (2024), leading the Goswami Laboratory โ a translational research group focused on epigenetic pathways that govern response and resistance to immune checkpoint therapy. She has authored over 80 peer-reviewed publications with 6,300+ citations and an h-index of 24. In 2025 she was recognised as a Top 1% Provider in the Nation by Press Ganey. In 2024 she was invited by the White House to serve as a panellist at the Inaugural US-India Cancer Dialogue โ a recognition of her standing as a bridge between Indian oncology talent and world-class American cancer research.
Dr. Goswami trained in India and completed her PhD and fellowship in the US. CancerFax can coordinate report review and second opinion support for international patients, including Indian families and the global Indian diaspora, subject to MD Anderson availability.
Why Consider Dr. Sangeeta Goswami?
Dr. Goswami combines rigorous bench-to-bedside research with direct patient care at one of the world's most respected cancer centres. Patients with kidney cancer, bladder cancer, and prostate cancer benefit from her dual expertise in clinical oncology and immunology.
Areas of Specialisation
Genitourinary oncology with deep expertise in immunotherapy and epigenetic modulation
Dr. Goswami's clinical and research practice is anchored in genitourinary cancers โ kidney, bladder, and prostate โ with particular expertise in immune checkpoint therapy and the molecular mechanisms that determine whether a patient will respond to it. Her dual appointment in the Departments of Genitourinary Medical Oncology and Immunology reflects the integration of her laboratory science with her direct patient care work.
Kidney Cancer (Renal Cell Carcinoma)
Advanced and metastatic kidney cancer management using the latest immunotherapy combinations and targeted agents.
- arrow_rightAnti-PD-1/PD-L1 therapy (nivolumab, pembrolizumab, avelumab) for eligible patients
- arrow_rightAnti-CTLA-4 combination therapy (ipilimumab) for clear cell and non-clear cell RCC
- arrow_rightSitravatinib plus nivolumab protocols (published Phase I-II trial, Science Translational Medicine 2022)
- arrow_rightTargeted therapy with belzutifan and other approved agents
- arrow_rightDebulking surgery planning integrated with immunotherapy (prospective pilot trial published, Nature Communications 2025)
- arrow_rightBiomarker-driven treatment selection using ARID1A mutation and CXCL13 expression profiling
Bladder Cancer (Urothelial Carcinoma)
Medical management of bladder cancer at all stages, including cisplatin-ineligible cases.
- arrow_rightNeoadjuvant PD-L1 plus CTLA-4 blockade for cisplatin-ineligible operable high-risk urothelial carcinoma (Nature Medicine 2020)
- arrow_rightMetastatic urothelial carcinoma management with immune checkpoint agents
- arrow_rightTertiary lymphoid structure (TLS) biomarker evaluation for immunotherapy selection
- arrow_rightActive investigational protocols targeting epigenetic pathways to improve immunotherapy response in bladder cancer
- arrow_rightClinical trial coordination for eligible patients with metastatic or advanced disease
Prostate Cancer
Advanced prostate cancer management with a focus on aggressive variant and treatment-resistant disease.
- arrow_rightAndrogen deprivation therapy and novel hormonal agents
- arrow_rightB7-H3-targeted therapy for aggressive variant prostate cancer (Prostate Cancer Foundation-funded research, 2022โ2025)
- arrow_rightPrecision oncology approach to treatment-resistant prostate cancer
Procedures & Clinical Approaches
Evidence-based systemic therapies for genitourinary cancers
Dr. Goswami's clinical practice at MD Anderson Cancer Center encompasses systemic cancer therapy, immunotherapy protocols, biomarker-guided treatment selection, clinical trial enrolment, and second opinion consultations for patients with kidney, bladder, and prostate cancer.
Immune Checkpoint Therapy
Medical OncologyAdministration and monitoring of anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents for genitourinary cancers, including combination immunotherapy protocols.
Targeted & Combination Therapy
Targeted TherapyMolecularly guided systemic therapy for eligible patients, including novel combinations under active trial investigation.
Biomarker Evaluation & Precision Staging
DiagnosisComprehensive molecular and immunological staging to guide optimal therapy selection.
Clinical Trial Participation
Complex DiseaseAccess to NIH/NCI-funded investigational protocols for patients with advanced or refractory disease.
Second Opinion Consultations
Second OpinionIndependent expert review of diagnosis, pathology, molecular results, and treatment plans for kidney, bladder, and prostate cancer patients.
Research & Publications
Translational immunotherapy research and peer-reviewed contributions
Dr. Goswami leads the Goswami Laboratory at MD Anderson Cancer Center, a translational research group focused on epigenetic pathways regulating response and resistance to immune-based cancer therapies. She has authored over 80 peer-reviewed publications with more than 6,300 citations and an h-index of 24. She serves as Associate Editor at Science Advances (2026โpresent) and is a member of the editorial review board at Frontiers in Immunology (2016โpresent).
Dr. Goswami leads multiple active NIH/NCI-funded trials at MD Anderson. CancerFax can help assess a patient's eligibility and coordinate the submission of medical records for review, subject to trial criteria and institutional availability.
Education & Training
Dr. Goswami's training spans three countries and two decades โ beginning with her medical degree in Assam, India, progressing through doctoral immunology research in Houston, Texas, and culminating in her clinical fellowship at MD Anderson Cancer Center.
Clinical Experience
Dr. Goswami joined MD Anderson Cancer Center as an Advanced Scholar in 2016 and has progressed to a tenured Associate Professorship in 2024, with dual appointments in Genitourinary Medical Oncology and Immunology. She is an inaugural member of the James P. Allison Institute and leads an independent translational research laboratory alongside her clinical practice.
Languages & International
Dr. Goswami conducts consultations in the following languages.
Dr. Goswami's fluency in English, Hindi, and Bengali makes her particularly accessible to patients and families from India and the South Asian diaspora worldwide. CancerFax facilitates report coordination and second opinion access for international patients.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Sangeeta Goswami
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Sangeeta Goswami's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Sangeeta Goswami's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Sangeeta Goswami before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Sangeeta Goswami's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Sangeeta Goswami's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Sangeeta Goswami's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Sangeeta Goswami
Dr. Goswami specialises in kidney cancer (renal cell carcinoma โ both clear cell and non-clear cell subtypes), bladder cancer (urothelial carcinoma), and prostate cancer, including aggressive variant and treatment-resistant disease. She treats these cancers at MD Anderson Cancer Center, Houston, using immune checkpoint therapy, targeted therapy, and clinical trial protocols.
Yes. CancerFax can coordinate the submission of your medical records โ including pathology reports, imaging, molecular profiling results, and treatment history โ to facilitate a second opinion request with Dr. Goswami at MD Anderson Cancer Center, subject to institutional availability and case acceptance. Submit your reports through the CancerFax portal and our oncology team will guide you through the next steps.
Dr. Goswami uses immune checkpoint inhibitors including anti-PD-1 agents (nivolumab, pembrolizumab), anti-PD-L1 agents (avelumab), and anti-CTLA-4 therapy (ipilimumab), often in combination. She has led and published clinical trials investigating sitravatinib plus nivolumab for anti-angiogenic-refractory clear cell RCC and has investigated debulking surgery combined with immunotherapy for metastatic disease. Treatment is guided by molecular and biomarker profiling including ARID1A and CXCL13 evaluation.
MD Anderson Cancer Center has an established International Patient Services programme and treats patients from across the world. Dr. Goswami trained at Gauhati Medical College in India and consults in English, Hindi, and Bengali, making her highly accessible to patients from India and the South Asian diaspora. CancerFax can assist with case preparation, report structuring, and coordination with MD Anderson's international team, subject to availability.
Dr. Goswami is a physician-scientist โ she leads both a translational research laboratory and an active clinical practice. She is a member of the James P. Allison Institute and holds NIH/NCI R37 funding for epigenetic resistance research in solid tumours. She was recognised as a Top 1% Provider in the Nation by Press Ganey (2025) and was invited by the White House as a panellist at the Inaugural US-India Cancer Dialogue (2024). Her patients benefit from access to investigational protocols and biomarker-driven treatment selection that may not be available at other centres.
Yes. Dr. Goswami is a Principal Investigator on multiple active clinical trials including a Cancer Research Institute-funded study on epigenetic reprogramming to improve immunotherapy response in metastatic renal cell carcinoma (2021โ2026), and an NIH/NCI R37-funded study targeting epigenetic machinery to overcome myeloid cell-mediated resistance in solid tumours (2023โ2030). CancerFax can help assess whether a patient may be eligible for current open trials at MD Anderson and assist with the records submission process.
Connect with Sangeeta Goswami Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.